YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma - Concepedia

Concepedia

Publication | Open Access

YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

DOI Full Paper Access

49

Citations

36

References

2014

Year

Jian Kong, Fandong Kong, Jun Gao, Qiangbo Zhang, Shuying Dong, Fang Gu, Shan Ke, Bing Pan, Qiang Shen, Hui‐Chuan Sun,

Molecular Cancer

Abstract

Our data show that sorafenib-YC-1 combination is a novel potent therapeutic agent that can target the STAT3 signaling pathway to inhibit HCC tumor growth.

References

	Year	Citations

Page 1